Here's Why Shares Of Intercept Jumped Nearly 10% On Friday
Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers'
Here's Why Shares Of Intercept Jumped Nearly 10% On Friday
Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers'
Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
Tobira Therapeutics Up 760% Following Allergan Buyout, Liver Drug A Key Focus